contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


sprint-biosciences-kommande-aktiviteter-1

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Sprint Bioscience is a research company. The company develops drug candidates that can fight cancer individually or in combination with other drugs. The company has a portfolio of projects that are focused on attacking parts of the processes of cancer cells. The business model is based on a project portfolio and developing projects in parallel in the preclinical phase and then entering into licensing agreements with the global pharmaceutical industry. The company is headquartered in Huddinge.

Sprint Bioscience

Sprint Bioscience AB (publ) summerar nedan bolagets kommande möten med potentiella partners och investerare under våren 2025. Utöver detta kommer bolaget att presentera vid ett antal internationella...

<div class="mfn-preamble"><p><strong>Sprint Bioscience AB (publ) summerar nedan bolagets kommande möten med potentiella partners och investerare under våren 2025. Utöver detta kommer bolaget att presentera vid ett antal internationella vetenskapliga konferenser. Information om dessa kommer att lämnas löpande och listan kan komma att uppdateras.</strong></p></div><div class="mfn-body"><p>För investerare:</p><p>22 januari<br>Redeye Fight Cancer, Stockholm, Sverige<br><a rel="noopener" href="https://www.redeye.se/events/1052608/redeye-theme-fight-cancer">https://www.redeye.se/events/1052608/redeye-theme-fight-cancer</a></p><p>13 mars <br>Swiss Nordic Bio, Zürich, Schweiz <br><a rel="noopener" href="https://www.swissnordicbio.com/">https://www.swissnordicbio.com/</a></p><p>Internationella partneringkonferenser:</p><p>17-19 mars<br>BIO-Europe Spring, Milano, Italien <br><a rel="noopener" href="https://informaconnect.com/bioeurope-spring/">https://informaconnect.com/bioeurope-spring/</a></p><p>16 -19 juni<br>Bio International Convention, Boston, USA <br><a rel="noopener" href="https://convention.bio.org/bio-2025">https://convention.bio.org/bio-2025</a></p></div><div class="mfn-footer mfn-contacts mfn-d3ce569ef85e"><p><strong class="mfn-heading-1">För vidare information, vänligen kontakta:</strong></p><hr><p>Johan Emilsson, vd, Sprint Bioscience<br>Tel: 08-411 44 55<br>Epost: <a rel="noopener" href="mailto:johan.emilsson@sprintbioscience.com">johan.emilsson@sprintbioscience.com</a></p></div><div class="mfn-footer mfn-about mfn-b8edf498b215"><p><strong class="mfn-heading-1">Om Sprint Bioscience AB (publ)</strong></p><hr><p>Sprint Bioscience utvecklar småmolekylära <em>first-in-class</em> läkemedelsprogram med fokus på onkologi. Med en fragmentbaserad läkemedelsutvecklingsmetod utvecklar bolaget läkemedelsprogram på ett tids- och resurseffektivt sätt som utlicensieras till globala läkemedelsbolag under den prekliniska fasen. Bolaget har framgångsrikt ingått flertalet licensavtal. Bolaget har sitt säte i Stockholm med laboratorier i Huddinge. Sprint Bioscience-aktien är noterad på Nasdaq First North Premier Growth Market och handlas under kortnamnet SPRINT. Ytterligare information finns på bolagets hemsida; <a rel="noopener" href="http://www.sprintbioscience.com.">www.sprintbioscience.com.</a><br>Certified Advisor är FNCA Sweden AB; <a rel="noopener" href="http://www.fnca.se.">www.fnca.se.</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Bifogade filer</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/ec18f326-02a6-4844-b165-742c46685f08/sprint-biosciences-kommande-aktiviteter.pdf" class="mfn-generated mfn-primary">Sprint Biosciences kommande aktiviteter</a></p></div>

Sprint Biosciences kommande aktiviteter

Talouden myyttejä murtamassa: Saksan teollisuus on menneen talven lumia

Federal Reserven korkopäätös: Riidankylväjät vauhdissa

Taloustieteen myyttejä murtamassa: Datakeskusinvestoinnit johtavat aina vain parempaan tekoälyyn

EKP:n korkopäätös: Tulkoon joulu (..ja talousoptimismi)

Nousuviikko takana, USA:n työllisyystaantuma ei edelleenkään luvuissa